a year ago

Pheon Therapeutics Secures $120 Million Series B to Advance Cancer Treatments

  • Pheon Therapeutics, a UK-based ADC specialist, has raised $120 million in Series B financing led by TCGX

  • The funds will be used to advance the company's ADC pipeline through clinical proof of concept and expand its technology platforms

  • Pheon's lead program is a first-in-class ADC targeting a novel target highly overexpressed in solid tumors across various cancers

  • The company plans to start its first Phase 1 clinical trial in 2024.

      • ProblemHealthcare

      "developing next generation ADCs for a wide range of hard-to-treat cancers"

      Solution

      "creating a pipeline of ADCs, based on novel targets and novel linker payloads, to treat solid tumors"

      Covered on